Published in AIDS on January 11, 2008
Optimal time on HAART for prevention of mother-to-child transmission of HIV. J Acquir Immune Defic Syndr (2011) 3.30
Effects of highly active antiretroviral therapy duration and regimen on risk for mother-to-child transmission of HIV in Johannesburg, South Africa. J Acquir Immune Defic Syndr (2010) 2.25
Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine. Clin Infect Dis (2010) 1.64
Progesterone supplementation for HIV-positive pregnant women on protease inhibitor-based antiretroviral regimens (the ProSPAR study): a study protocol for a pilot randomized controlled trial. Pilot Feasibility Stud (2016) 1.40
Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception. Sex Transm Infect (2008) 1.31
Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11). PLoS Med (2014) 1.16
Mother-to-child transmission of HIV in a community-based antiretroviral clinic in South Africa. S Afr Med J (2010) 1.13
Progress in prevention of mother-to-child transmission of HIV infection in Ukraine: results from a birth cohort study. BMC Infect Dis (2009) 1.11
Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. Br J Clin Pharmacol (2008) 1.04
Low rates of mother-to-child HIV transmission in a routine programmatic setting in Lilongwe, Malawi. PLoS One (2013) 1.00
Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy. AIDS (2010) 0.98
Use of zidovudine-sparing HAART in pregnant HIV-infected women in Europe: 2000-2009. J Acquir Immune Defic Syndr (2011) 0.94
Insufficient antiretroviral therapy in pregnancy: missed opportunities for prevention of mother-to-child transmission of HIV in Europe. Antivir Ther (2011) 0.92
Kinetics and determining factors of the virologic response to antiretrovirals during pregnancy. Infect Dis Obstet Gynecol (2010) 0.89
Vertical transmission of HIV in Belgium: a 1986-2002 retrospective analysis. Eur J Pediatr (2008) 0.88
Short communication: Use of raltegravir in late-presenting HIV-infected pregnant women. AIDS Res Hum Retroviruses (2013) 0.88
Time of HIV Diagnosis and Engagement in Prenatal Care Impact Virologic Outcomes of Pregnant Women with HIV. PLoS One (2015) 0.87
Mode of delivery in HIV-infected pregnant women and prevention of mother-to-child transmission: changing practices in Western Europe. HIV Med (2010) 0.87
Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome. Retrovirology (2009) 0.86
Use of neonatal antiretroviral prophylaxis for prevention of mother-to-child transmission of HIV is decreasing in Western Europe. Clin Infect Dis (2009) 0.86
The breadth and titer of maternal HIV-1-specific heterologous neutralizing antibodies are not associated with a lower rate of mother-to-child transmission of HIV-1. J Virol (2012) 0.85
Point-of-care CD4 testing to inform selection of antiretroviral medications in south african antenatal clinics: a cost-effectiveness analysis. PLoS One (2015) 0.85
Adherence to antiretroviral therapy during pregnancy and the first year postpartum among HIV-positive women in Ukraine. BMC Public Health (2014) 0.83
Safety and tolerability of antiretrovirals during pregnancy. Infect Dis Obstet Gynecol (2011) 0.82
Placental transfer of darunavir in an ex vivo human cotyledon perfusion model. Antimicrob Agents Chemother (2014) 0.82
A randomized controlled trial to assess safety, tolerability, and antepartum viral load with increased lopinavir/ritonavir dosage in pregnancy. AIDS Patient Care STDS (2013) 0.80
HIV-1 proteins, Tat and gp120, target the developing dopamine system. Curr HIV Res (2015) 0.80
A three-source capture-recapture estimate of the number of new HIV diagnoses in children in France from 2003-2006 with multiple imputation of a variable of heterogeneous catchability. BMC Infect Dis (2012) 0.79
The impact of revised PMTCT guidelines: a view from a public sector ARV clinic in Cape Town, South Africa. J Acquir Immune Defic Syndr (2013) 0.79
Randomized noninferiority trial of two maternal single-dose nevirapine-sparing regimens to prevent perinatal HIV in Thailand. AIDS (2015) 0.78
German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008. Eur J Med Res (2009) 0.78
Prevention of vertical HIV transmission and management of the HIV-exposed infant in Canada in 2014. Can J Infect Dis Med Microbiol (2014) 0.78
Detectable Viral Load in Late Pregnancy among Women in the Rwanda Option B+ PMTCT Program: Enrollment Results from the Kabeho Study. PLoS One (2016) 0.78
Unexpected vertical transmission of HIV infection. Eur J Pediatr (2013) 0.77
The last and first frontier - emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants. J Int AIDS Soc (2015) 0.76
Trypanosoma cruzi (Chagas' disease agent) reduces HIV-1 replication in human placenta. Retrovirology (2008) 0.76
Placental transfer of rilpivirine in an ex vivo human cotyledon perfusion model. Antimicrob Agents Chemother (2015) 0.76
Birth defects in a cohort of infants born to HIV-infected women in Spain, 2000-2009. BMC Infect Dis (2014) 0.75
Antenatal atazanavir: a retrospective analysis of pregnancies exposed to atazanavir. Infect Dis Obstet Gynecol (2014) 0.75
Antiretroviral therapy: when to start. Infect Dis Clin North Am (2014) 0.75
Getting to 90-90-90 in paediatric HIV: What is needed? J Int AIDS Soc (2015) 0.75
[Study of risk factors for HIV transmission from mother to child in the strategy «option A» in Lubumbashi, Democratic Republic of Congo]. Pan Afr Med J (2015) 0.75
Complications of cesarean deliveries among HIV-infected women in the United States. AIDS (2014) 0.75
HIV Prophylaxis in High Risk Newborns: An Examination of Sociodemographic Factors in an Inner City Context. Can J Infect Dis Med Microbiol (2016) 0.75
Antiretroviral treatment, viral load of mothers & perinatal HIV transmission in Mumbai, India. Indian J Med Res (2013) 0.75
Prenatal ultrasound screening for fetal anomalies and outcomes in high-risk pregnancies due to maternal HIV infection: a retrospective study. Infect Dis Obstet Gynecol (2013) 0.75
Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy. HIV AIDS (Auckl) (2009) 0.75
Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog (2013) 6.14
Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med (2007) 5.58
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med (2015) 5.30
HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis (2005) 3.77
Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol (2007) 3.69
Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med (2010) 3.54
Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol (2005) 3.36
HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science (2010) 3.29
Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Côte d'Ivoire. AIDS (2004) 3.24
Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest (2009) 2.92
Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis (2010) 2.90
Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS (2008) 2.84
Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. J Acquir Immune Defic Syndr (2007) 2.72
Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. Haematologica (2005) 2.66
Influenza burden of illness: estimates from a national prospective survey of household contacts in France. Arch Intern Med (2002) 2.48
Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1. Clin Infect Dis (2004) 2.46
Contraceptive use, protected sexual intercourse and incidence of pregnancies among African HIV-infected women. DITRAME ANRS 049 Project, Abidjan 1995-2000. Int J STD AIDS (2002) 2.44
Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol (2010) 2.35
Drug administration errors and their determinants in pediatric in-patients. Int J Qual Health Care (2005) 2.31
Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma. AIDS (2008) 2.27
Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One (2009) 2.23
Field acceptability and effectiveness of the routine utilization of zidovudine to reduce mother-to-child transmission of HIV-1 in West Africa. AIDS (2002) 2.18
Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol (2009) 2.17
PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med (2009) 2.16
Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PLoS One (2008) 2.14
Frequent occurrence of chronic hepatitis B virus infection among West African HIV type-1-infected children. Clin Infect Dis (2008) 2.12
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet (2013) 2.11
Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire. J Infect Dis (2006) 2.08
Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J Infect Dis (2005) 2.03
Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS (2010) 2.03
CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis (2006) 2.02
Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens. AIDS (2006) 2.01
Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics (2003) 1.91
Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006. Clin Infect Dis (2008) 1.90
LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01). J Med Virol (2009) 1.88
Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS (2003) 1.88
Universal antiretroviral therapy for pregnant and breast-feeding HIV-1-infected women: towards the elimination of mother-to-child transmission of HIV-1 in resource-limited settings. Clin Infect Dis (2009) 1.88
Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology (2009) 1.84
Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost? Clin Infect Dis (2012) 1.80
Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS (2007) 1.77
Field evaluation of a rapid human immunodeficiency virus (HIV) serial serologic testing algorithm for diagnosis and differentiation of HIV type 1 (HIV-1), HIV-2, and dual HIV-1-HIV-2 infections in West African pregnant women. J Clin Microbiol (2004) 1.73
18-month effectiveness of short-course antiretroviral regimens combined with alternatives to breastfeeding to prevent HIV mother-to-child transmission. PLoS One (2008) 1.69
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. Lancet Infect Dis (2013) 1.68
SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID. Blood (2013) 1.68
Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother (2013) 1.66
HIV cure and eradication: how will we get from the laboratory to effective clinical trials? AIDS (2011) 1.64
Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis (2005) 1.64
Undetectable viremia without antiretroviral therapy in patients with HIV seroconversion: an uncommon phenomenon? Clin Infect Dis (2005) 1.64
French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr (2005) 1.63
Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers. Blood (2011) 1.62
Termination of pregnancy following prenatal diagnosis in France: how severe are the foetal anomalies? Prenat Diagn (2010) 1.61
Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS (2006) 1.61
Characteristics of HIV-infected women who do not receive preventive antiretroviral therapy in the French Perinatal Cohort. J Acquir Immune Defic Syndr (2003) 1.61
Monitoring cytomegalovirus infection in adult and pediatric bone marrow transplant recipients by a real-time PCR assay performed with blood plasma. J Clin Microbiol (2003) 1.58
HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Côte d'Ivoire: the ANRS 1236 study. J Med Virol (2004) 1.55
Cesarean section for HIV-infected women in the combination antiretroviral therapies era, 2000-2010. Am J Obstet Gynecol (2013) 1.54
Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study). AIDS (2007) 1.53
The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS (2004) 1.52
Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS (2004) 1.49
Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS (2009) 1.49
Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS (2006) 1.45
HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS (2006) 1.45
Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS (2004) 1.44
Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity. AIDS (2006) 1.43
A modified γ-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med (2014) 1.42
Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pre-treated HIV-infected men. AIDS (2004) 1.42
HIV-DNA in rectal cells is well correlated with HIV-DNA in blood in different groups of patients, including long-term non-progressors. AIDS (2008) 1.41
Cidofovir may be deleterious in BK virus-associated nephropathy. Transplantation (2010) 1.41
Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr (2005) 1.41
X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood (2010) 1.40
Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients. AIDS (2012) 1.38
Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load <500 copies/ml at delivery: a case-control study nested in the French perinatal cohort (EPF-ANRS CO1). Clin Infect Dis (2010) 1.36
Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established? Clin Infect Dis (2009) 1.35
Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire. J Acquir Immune Defic Syndr (2011) 1.34